Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KIR2DL1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KIR2DL1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View KIR2DL1 Products |
| Gene Delivery | KIR2DL1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View KIR2DL1 Products |
| Benchmark Ab | Anti-KIR2DL1 (Sequence of Lirilumab) Recombinant positive control. |
View KIR2DL1 Products |
| Validator | KIR2DL1 siRNA Set For knockdown verification. |
View KIR2DL1 Products |
| Related Target A | KIR2DL2 Homologous inhibitory receptor; crucial for selectivity and cross-reactivity screening. |
View KIR2DL2 Products |
| Related Target B | HLA-C Ligand for KIR2DL1; essential for functional blocking and binding competition assays. |
View HLA-C Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-reactivity screening with homologous KIRs (KIR2DL2/3) | Human/Cyno ortholog proteins and homologous panels available with >95% purity |
| Cell-based functional validation (NK inhibition) | Lentivirus for stable KIR2DL1-expressing reporter cell lines (HEK293/Jurkat) |
| Lack of Controls | Clinical Benchmark Antibodies (Lirilumab biosimilar) included |
| False Positives | Validated siRNA included for target knockdown specificity checks |
Live KIR2DL1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KIR2DL1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to multispecific NK cell engagers (NKCEs) and combination regimens. As first-generation therapies reach the clinic, the next wave of R&D is targeting precise allele selectivity and synergistic combinations with T-cell checkpoint inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Innate Pharma, Bristol Myers Squibb | Hematological Malignancies, Solid Tumors | Receptor blocking & HLA-C competition assays (Need high-purity ECD-Fc) |
| Multispecific NKCEs | Sanofi, Innate Pharma | Solid Tumors | Cross-linking & selectivity assays (Need homologous KIR panel) |
| CAR-NK | Takeda, Fate Therapeutics | B-cell Lymphomas, Solid Tumors | Target expression confirmation & escape validation (Need Lentivirus & siRNA) |